BioSpace News Archive

Covetrus, a global leader in animal-health technology and services, announced that Benjamin Wolin will become the company’s president and chief executive officer, transitioning from the acting role he has held since October 2019.

Evofem Biosciences, Inc. will hold a webcast and conference call to discuss the Company’s financial results and business highlights for the fourth quarter and year ended December 31, 2019..

Phase 2 interim data at three months, expected in 3Q 2020, intended to inform Phase 3 dose selection

Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Emergent Connect, LLC is launching its newest addition to their cloud-based software that will prioritize radiologist workflow.

Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY) today announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients.

Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, announced that it has priced an underwritten public offering of 8,520,000 shares of its common stock at a price to the public of $23.50 per share.

AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, including rare diseases with high unmet medical needs, announces the appointment of the experienced pharmaceutical executive Michael Soldan, PhD, as its Chief Executive Officer.

The designation is based on results from a Phase II trial, which suggested Esbriet slowed disease progression in patients with uILD at 24 weeks

GenSight Biologics announced that the bilateral visual recovery observed with GS010 in the REVERSE and RESCUE Phase III trials will be presented and discussed at the 46th Annual Meeting of the North American Neuro-Ophthalmology Society - Amelia Island, Florida - March 7-12, 2020.